Drug intelligence / Profile preview

protoxin-I

Development stage
Preclinical
Modality
Peptides
Administration
Intravenous, Subcutaneous
01

Overview

Protoxin-I (ProTx-I) is a 35-amino acid peptide toxin originally isolated from the venom of the Peruvian green velvet tarantula (*Thrixopelma pruriens*). It belongs to the inhibitory cystine knot (ICK) family of peptides. ProTx-I acts as a potent, non-selective inhibitor of various voltage-gated sodium (Nav) channels, including Nav1.1, Nav1.2, Nav1.5, Nav1.7, and Nav1.8. It functions as a gating modifier by binding to the voltage-sensor domains (VSDs) of these channels, specifically shifting the voltage dependence of activation toward more depolarized potentials. In addition to sodium channels, ProTx-I has been shown to inhibit T-type voltage-gated calcium channels (Cav3.1). Although primarily used as a high-affinity pharmacological tool in research, it is studied for its potential to inhibit metastasis in sodium-regulated cancers and its role in modulating nociceptive signaling for pain management.

Other names
Thrixopelma pruriens toxin 1Spider toxin ProTx-I
02

Targets

CACNA1G (T-type Calcium Channel Protein Subunit Alpha-1G)SCN11A (NaV1.9)TRPA1 (Transient receptor potential cation channel subfamily A member 1)SCN2A (Voltage-gated sodium channel protein type 2 subunit alpha)SCN7A (NaV2.1)SCN10A (Sodium channel protein type X alpha subunit)CACNA1I (Voltage-dependent T-type calcium channel subunit alpha-1I)CACNA1H (T-type voltage-gated calcium channel 3.2)SCN5A (Sodium channel protein type 5 subunit alpha)

Beyond the preview

Go deeper on protoxin-I.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on protoxin-I.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call